Taiwan Liposome Company, Ltd. Initial Public Offering
11/27/2018

Davis Polk advised the book-running manager and representative of the underwriters in connection with the initial public offering by Taiwan Liposome Company, Ltd. of American Depositary Shares. The ADSs are listed on the Nasdaq Global Market under the symbol “TLC.”

Headquartered in Taipei, Taiwan, Taiwan Liposome Company is a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines that combine a proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients.

The Davis Polk corporate team included partner Bruce K. Dallas and associates Emily Roberts and Beth LeBow. Associate Jason J. Bang provided intellectual property and technology advice. The tax team included partner Rachel D. Kleinberg and associate Rebecca A. Rosen. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.